Skip to main content
. 2024 Feb 13;30(3):716–729. doi: 10.1038/s41591-024-02808-y

Fig. 2. PFS and OS with durvalumab–ceralasertib and with durvalumab plus olaparib, danvatirsen or oleclumab in HUDSON.

Fig. 2

a,b, Kaplan–Meier analysis of PFS (a) and OS (b) among all patients who received durvalumab–ceralasertib or who received durvalumab plus olaparib, danvatirsen or oleclumab on HUDSON.